论文部分内容阅读
1984年3—5月,我们应用日本三和化学研究所提供的肝提取物制剂—Adelavin 9号,治疗20例慢性肝炎患者。现将治疗情况报告如下。一、对象和方法(一)治疗对象:本组慢性肝炎病例的诊断、分型标准,参照1978年杭州全国肝炎学术会议关于病毒性肝炎的诊治意见,选择20例乙型肝炎表面抗原(HBsAg)阳性、肝功能试验有一定程度改变的成年慢性病毒性肝炎病例作为本组治疗对象。20例慢性肝炎患者中,男性患者16例,女性患者4例。年龄在19—56岁之间,平均为37.2岁。临床诊断为慢性活动性肝炎13例,慢性迁延性肝炎7例。黄疸型2例,无黄疸型18例,全部患者的血清HBsAg 均为阳性(Rpha法和Elisa 法)。
From March to May 1984, we treated 20 patients with chronic hepatitis with Adelavin No. 9, a liver extract formulation from Japan’s Sanwa Chemical Institute. The treatment is now reported as follows. First, the object and method (A) of the treatment group: the group of patients with chronic hepatitis diagnosis, classification criteria, with reference to the 1978 Hangzhou National Symposium on hepatitis diagnosis and treatment of viral hepatitis, select 20 cases of hepatitis B surface antigen (HBsAg) Positive, liver function tests to a certain extent, adult chronic viral hepatitis as the treatment group. Of the 20 patients with chronic hepatitis, 16 were male and 4 were female. The age of 19-56 years old, with an average of 37.2 years old. Clinical diagnosis of chronic active hepatitis in 13 cases, chronic persistent hepatitis in 7 cases. Jaundice in 2 cases, jaundice in 18 cases, all patients were positive for serum HBsAg (Rpha method and Elisa method).